A new Alzheimer’s disease drug, Leqembi (lecanemab), will be covered by the Veterans Affairs for some patients, making the VA the first insurer to cover the drug.

Wary consumers can be convinced to allow AI into their healthcare habits by communications campaigns tuned to the ancient rhetorical categories of ethos, pathos and logos. 

Although advanced imaging exams have proven benefits in defining disease severity, new data indicate that more sophisticated studies might not impact outcomes as much as previously thought. 

“Together, Pfizer and Seagen seek to accelerate the next generation of cancer breakthroughs and bring new solutions to patients by combining the power of Seagen’s antibody-drug conjugate technology with the scale and strength of Pfizer’s capabilities and expertise," says Pfizer Chairman and CEO Albert Bourla, PhD.

"We have been in your network a long time and have had time to study your business. We have stolen your confidential information and are ready to publish it," the ransomware group threatened.

Published in JACR, the new white paper outlines four areas of consensus between the two specialties. 

Redundant brain pathways can serve as pre-symptomatic indicators of mild cognitive impairment (MCI) in aging individuals, allowing care teams to design first-line neuropsychological exercises for slowing the possible approach of Alzheimer’s disease.

Radiologists took to Twitter to voice their frustrations over the worsening situation, while the manufacturer issued an update Thursday.